Skip to main content
SpringerLink
Log in

Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Summary

Rapid achievement of reperfusion with thrombolytic therapy or primary angioplasty has made a dramatic impact on improving the survival of patients with acute myocardial infarction (MI). Restoring infarct-related artery patency early after the onset of MI minimizes infarct size, reduces the degree of left ventricular dysfunction, and improves survival. Several recent studies have confirmed the benefit of reducing time to treatment with thrombolysis (between the onset of pain to initiation of thrombolysis), and that of more rapid drug reperfusion time with more aggressive thrombolytic regimens (between initiation of thrombolytic therapy and actual achievement of reperfusion). Furthermore, these effects are additive, confirming the benefit of rapid reperfusion. For primary angioplasty, the same relationship has been observed—more rapid treatment appears to be associated with improved outcome. The “door-to-balloon” time is a major determinant of overall time to reperfusion, and as such is a crucial component of the overall strategy. Integrating the experience in trials of thrombolytic therapy and primary angioplasty, a clear relationship exists between higher rates of early reperfusion and lower mortality. Thus, time to reperfusion appears to be the critical modulator in both thrombolysis and primary angioplasty.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–401.

    Google Scholar 

  2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.

    Google Scholar 

  3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.

    Google Scholar 

  4. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation 1989;79:441–444.

    Google Scholar 

  5. Braunwald E. The open-artery theory is alive and well—again. N Engl J Med 1993;329:1650–1652.

    Google Scholar 

  6. Reimer KA, Lowe JE, Rasmussen NM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977;56:786–794.

    Google Scholar 

  7. Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction. Comparison with conventionally treated patients. Clin Cardiol 1979;2:92–105.

    Google Scholar 

  8. Ganz W, Buchbinder N, Marcus H, et al. Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 1981;101:4–13.

    Google Scholar 

  9. Stadius ML, Davis K, Maynard C, Ritchie JL, Kennedy JW. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. Circulation 1986;74:701–711.

    Google Scholar 

  10. Dalen JE, Gore JM, Braunwald E, et al. Six and twelvemonth follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Am J Cardiol 1988;62:179–185.

    Google Scholar 

  11. Belenkie I, Thompson CR, Manyari DE, et al. Importance of effective, early and sustained reperfusion during acute myocardial infarction. Am J Cardiol 1989;63:912–916.

    Google Scholar 

  12. Flygenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E, for the TIMI Investigators. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? (abstract) J Am Coll Cardiol 1991;17(Suppl A):275A.

    Google Scholar 

  13. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL, for the TEAM-2 Investigators. Does Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 Study. J Am Coll Cardiol 1992;19:1–10.

    Google Scholar 

  14. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL, for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: Ventriculographic, enzymatic and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993;87:1829–1839.

    Google Scholar 

  15. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602–1610.

    Google Scholar 

  16. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993–1003.

    Google Scholar 

  17. Lincoff AM, Topol EJ, Califf RM, et al. Significance of a coronary artery with Thrombolysis in Myocardial Infarction grade 2 flow “patency” (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials). Am J Cardiol 1995;75:871–876.

    Google Scholar 

  18. The GUSTO Angiographic Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–1622.

    Google Scholar 

  19. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923–1928.

    Google Scholar 

  20. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. N Engl J Med 1985; 312:932–936.

    Google Scholar 

  21. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994;49:1–8.

    Google Scholar 

  22. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71.

    Google Scholar 

  23. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71–75.

    Google Scholar 

  24. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.

    Google Scholar 

  25. Cannon CP, Love TW, McCabe CH, et al. TNK-tissue plasminogen activator in myocardial infarction (TIMI) 10: Results of the initial patients in the TIMI 10 Pilot—a Phase 1, pharmacokinetics trial (abstract). Circulation 1995; 92(Suppl I):I-415.

    Google Scholar 

  26. Weaver WD, Bode C, Burnett C, et al. Reteplase vs. Alteplase Patency Investigation During myocardial infarction trial (RAPID 2) (abstract). J Am Coll Cardiol 1995;Special Issue:87A.

  27. Ohman EM, Kleiman NS, Talley JD, et al. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction (abstract). Circulation 1994;90:I-564.

    Google Scholar 

  28. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994;1:27–34.

    Google Scholar 

  29. Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II (abstract). Circulation 1991;84:II-230.

    Google Scholar 

  30. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 1995;91:1659–1668.

    Google Scholar 

  31. Topol EJ, Califf RM, Lee KL, on behalf of the GUSTO Investigators. More on the GUSTO trial (letter). N Engl J Med 1994;331:277–278. Published errata appear in N Engl J Med 1994;331:687, 1323.

    Google Scholar 

  32. O'Keefe JH, Rutherford BD, McConahay DR, et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989;64:1221–1230.

    Google Scholar 

  33. Cannon CP. Time to treatment: A crucial factor in thrombolysis and primary angioplasty. J Thromb Thrombolysis, in press.

  34. Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 1990;82:1510–1513.

    Google Scholar 

  35. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm— paradoxic or predictable? Circulation 1993;88:296–306.

    Google Scholar 

  36. National Heart Attack Alert Program Coordinating Committee—60 Minutes to Treatment Working Group. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311–329.

    Google Scholar 

  37. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Patient/bystander recognition and action: Rapid identification and treatment of acute myocardial infarction. National Institute of Health; 1993: NIH Publication No. 93-3303.

  38. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Staffing and equipping emergency medical services systems: Rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:58–65.

    Google Scholar 

  39. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Emergency medical dispatching: Rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:67–73.

    Google Scholar 

  40. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. 9–1–1: Rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:188–195.

    Google Scholar 

  41. Lambrew CT. The National Heart Attack Alert Program: A review. J Thromb Thrombolysis 1994;1:153–156.

    Google Scholar 

  42. Gaspoz J-M, Unger P-F, Urban P, et al. Impact of a public campaign on pre-hospital time delays in suspected acute myocardial infarction (abstract). Circulation 1993;88:I-13.

    Google Scholar 

  43. Blohm M, Herlitz J, Hartford M, et al. Consequences of a media campaign focusing on delay in acute myocardial infarction. Am J Cardiol 1992;69:411–413.

    Google Scholar 

  44. Weaver WD, Eisenberg MC, Martin JS, et al. Myocardial Infarction Triage and Intervention Project—Phase I: Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990;15: 925–931.

    CAS  PubMed  Google Scholar 

  45. Karagounis L, Ipsen SK, Jessop MR, et al. Impact of fieldtransmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1990;66:786–791.

    Google Scholar 

  46. Lambrew CT, Weaver WD, French WJ, Bowlby L, Rubison M, for the National Registry of Myocardial Infarction (NRMI). Impact of hospital protocols on time to treatment with thrombolytic therapy (door to drug time) (abstract). J Am Coll Cardiol 1994;Special Issue:14A.

  47. Rawles J, on behalf of the GREAT Group. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994;23:1–5.

    Google Scholar 

  48. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Eng J Med 1993;329: 383–389.

    Google Scholar 

  49. Sharkey SW, Brunette DD, Ruiz E, et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989;262:3171–3174.

    Google Scholar 

  50. Kline EM, Smith DD, Martin JS, for the GUSTO Time to Treatment Study Group. GUSTO Time to Treatment Substudy: Results of the phase II randomized trial (abstract). Circulation 1993;88:I-337.

    Google Scholar 

  51. Cannon CP, Henry TD, Schweiger MJ, et al. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: Results of the multicenter TIMI 9 Registry (abstract). J Am Coll Cardiol 1995; Special Issue:231A.

  52. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509–1514.

    Google Scholar 

  53. Pell ACH, Miller HC, Robertson CE, Fox KAA. Effect of “fast track” admission for acute myocardial infarction on delay to trombolysis. Br Med J 1992;304:83–87.

    Google Scholar 

  54. Lambrew CT. Emergency department triage of patients with nontraumatic chest pain. ACC Curr J Rev 1995;4:61–62.

    Google Scholar 

  55. Krall SP, Reese CL, Donahue L. Effect of continuous quality improvement methods on reducing triage time to thrombolytic interval for acute myocardial infarction. Acad Emerg Med 1995;2:603–609.

    Google Scholar 

  56. Kopecky SL, Siska MJ, Jurek JA, et al. Method of reducing emergency room time to treatment of acute myocardial infarction (abstract). J Am Coll Cardiol 1995;Special Issue: 206.

  57. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673–679.

    Google Scholar 

  58. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–684.

    Google Scholar 

  59. Rogers WJ, Dean LS, Moore PB, et al. Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1994;74:111–118.

    Google Scholar 

  60. Tiefenbrunn AJ, Chandra NC, French WJ, Rogers WJ. Experience with primary PTCA compared to alteplase in patients with acute myocardial infarction (abstract). Circulation 1995;92(Suppl I):I-138.

    Google Scholar 

  61. Every N, Weaver WD, Parsons L, Martin JS, for the MITI Project Investigators. Direct PTCA vs. thrombolysis: Immediate and one year outcome and procedure utilization for the two treatment strategies (abstract). Circulation 1995; 92(Suppl I):I-138.

    Google Scholar 

  62. Neuhaus K-L, Vogt A, Harmjanz, D, v. Leitner E, Wirtzfeld A, Neiderer W, Merx W, for the ALKK-study group: Primary angioplasty for acute myocardial infarction: results from a German multicenter registry, (abstract) J Am Coll Cardiol 1996;27:62A.

    Google Scholar 

  63. de Boer MJ, Suryapranata H, Hoorntje JCA, et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation 1994;90:753–761.

    Google Scholar 

  64. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685–691.

    Google Scholar 

  65. O'Neill WW, Brodie BR, Ivanhoe R, et al. Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). Am J Cardiol 1994;73:627–634.

    Google Scholar 

  66. Grines C, Marsalese D, Brodie B, et al. Acute cath provides the best method of risk stratifying MI patients (abstract). Circulation 1995;92(Suppl I):I-531.

    Google Scholar 

  67. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs 1992;44:293–325.

    Google Scholar 

  68. Neuhaus K-L, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with frontloaded administration of alteplase: Results of the rt-PAAPSAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19:885–891.

    Google Scholar 

  69. Cannon CP, Lambrew CT, Tiefenbrunn AJ, et al. Influence of door-to-balloon time on mortality in primary angioplasty Results in 3,648 patients in the Second National Registry of Myocardial Infarction (NRMI-2) (abstract). J Am Coll Cardiol 1996;27:61a-62a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Department of Medicine, Harvard Medical School, and Brigham and Women's Hospital, Boston, Massachusetts, USA

    Christopher P. Cannon & Eugene Braunwald

Authors
  1. Christopher P. Cannon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugene Braunwald
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cannon, C.P., Braunwald, E. Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty. J Thromb Thrombol 3, 117–125 (1996). https://doi.org/10.1007/BF00132404

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00132404

Key Words

Search

Navigation